Rapamycin and Aging: Reviewing the Geroprotector Evidence

By Longevity Lab · Published: July 21, 2026

Based on peer-reviewed research — full source list at the end of this article. This is educational information, not medical advice.

Rapamycin is the most convincing geroprotector in animal research and the most uncertain one in people: in the Interventions Testing Program (ITP) of the US National Institute on Aging it raised the median lifespan of mice by 10–25%, reproducibly, even when dosing began in old age. In humans there is no evidence that rapamycin extends life, and it remains a prescription immunosuppressant taken off-label rather than a supplement. It is also the most discussed compound in aging science, and it carries the most hope and the most speculation. This article covers what the studies actually show, how the animal data differ from the human data, and why geriatricians urge caution.

What rapamycin is and how it affects aging

Rapamycin, known internationally as sirolimus, was discovered in the 1970s as a product of a Streptomyces bacterium from Easter Island (Rapa Nui, which is where the name comes from). Its first uses were as an immunosuppressant to prevent transplant rejection and as a coating on cardiac stents.

Its molecular target is the mTOR complex (mechanistic target of rapamycin), and more precisely mTORC1. This protein complex works as a nutrient sensor: when food is plentiful, mTOR switches on cell growth and protein synthesis and suppresses autophagy, the cell’s self-cleaning mechanism. Chronic overactivation of mTOR accelerates cellular aging. Rapamycin partly dampens that signal, mimicking the effect of caloric restriction.

What the research on rapamycin shows

Animal data

This is the strongest part of the evidence. In the Interventions Testing Program (ITP) run by the US National Institute on Aging, rapamycin reproducibly extended the lifespan of mice in several independent laboratories, a result only a handful of compounds have ever produced. Median lifespan rose by 10–25%, and the effect held even when dosing started in mice that were already old.

Beyond lifespan itself, the animals improved on individual health markers: heart function, immune response, tendon condition, and a lower rate of some tumors. Similar effects have been shown in yeast, worms and flies, which points to an evolutionarily ancient mechanism.

What makes these data especially valuable is where they come from. The ITP is the only system that tests a compound in three independent laboratories at once under a single protocol, specifically to filter out chance and irreproducible results. Only a few compounds have passed that filter, and rapamycin is the most convincing of them. The effect also held in mice of both sexes and did not depend on whether dosing started in youth or in old age, a rare combination for a geroprotector.

Human data

There is no direct evidence that rapamycin extends human life, and there will not be any for years, because trials like that run for decades. What does exist: small studies in which low doses of the analog everolimus improved the response to influenza vaccine in older adults, offsetting part of the age-related weakening of immunity. Early safety trials of intermittent schedules in healthy people are under way, PEARL among them. Their job is to assess tolerability, not to prove longevity.

A separate source of indirect data is decades of transplant medicine, where patients take sirolimus for years. It answers nothing about longevity, because these patients are ill to begin with, but it has accumulated a large body of information on the safety of long-term use. That experience is what suggested intermittent dosing: a constant dose hits immunity too hard, while short pulses could in theory preserve the geroprotective effect without chronic immunosuppression.

Rapamycin doses used in research

One thing to be clear about: no single “longevity protocol” exists, and the figures below describe what has been studied rather than what you should take.

The logic behind weekly schedules: press briefly on mTORC1 without suppressing mTORC2, which is tied to the metabolic side effects, and without switching off immunity for long. Whether that works for longevity in people is still an open question.

Safety and contraindications

Rapamycin is not a supplement. It is a potent prescription drug. The known side effects of regular use are mouth ulcers (aphthous stomatitis), raised lipid and glucose levels, edema, slower wound healing, and greater susceptibility to infection because of immunosuppression. It is contraindicated in active infection, before surgery, and in pregnancy. Because those metabolic shifts show up in routine bloodwork, lipids and fasting glucose are worth reading together rather than as isolated numbers, which is what the METS-IR: metabolic score for insulin resistance does with glucose, triglycerides and HDL.

The gray market is a problem of its own: people order the drug without a prescription and take it without lab monitoring. That is dangerous, because the response varies from person to person and the drug interacts with many other medications.

Where rapamycin sits among the paths to longevity

It helps to see rapamycin as one point on the mTOR–AMPK axis, where almost every known way of influencing metabolic aging converges. At one end of the axis is the braking of the growth signal (mTOR), at the other the activation of the energy-deficit signal (AMPK).

Every intervention that has held up over time moves the system the same way, toward repair rather than growth. Caloric restriction and intermittent fasting lower mTOR through food; metformin and berberine activate AMPK; rapamycin hits mTOR directly and most precisely. That explains why it produces the strongest effect in animals, and also why it has the most pronounced side-effect profile: direct pharmacological intervention is more powerful than lifestyle, and also blunter.

The practical value of that frame: the foundation of longevity is food, movement and sleep, which shift the same axis safely and without a prescription. Pharmacological geroprotectors such as rapamycin are a layer being studied on top of that foundation, not a substitute for it. If you want the food side of that axis in detail, the human evidence on eating windows is laid out in Intermittent Fasting and Aging, Minus the Hype.

Verdict: how justified is taking rapamycin

Rapamycin is the most convincing geroprotector in animals and the most uncertain one in humans. For mice, life extension is a proven result; for people it is a hypothesis that researchers have only started to test.

A sensible position as of 2026: follow the results of the clinical trials and do not self-medicate. Tracking your own aging trajectory is the part you can act on today, and a blood-based clock such as the PhenoAge Calculator — biological age from a blood test turns a standard panel into a single number you can follow year to year. For comparison, metformin has more human data and a lower risk when used incorrectly, although it is not an “anti-aging pill” either.

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.